Zogenix Gets Approval of New Drug to Treat Rare Type of Childhood Epilepsy

A Zogenix’s new drug that treats a rare and severe type of epilepsy was approved by the Food and Drug Administration on Thursday, a decision that clears the way for the company to compete against a recently approved drug derived from marijuana.

The drug Zogenix, called Fintepla, is a liquid solution given to children born with Dravet syndrome, a severe type of epilepsy that causes frequent and prolonged seizures from the first year of life. Approximately 250 children in the United States are born with Dravet each year, and it affects about 20,000 people overall.

Unlock this item by subscribing to STAT Plus and enjoy your first 30 days free!